Pacira BioSciences
-
Financial
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL…
Read More » -
Extremities
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…
Read More » -
Recon
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours.…
Read More » -
Biologics
Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes
PARSIPPANY, N.J., July 02, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain…
Read More » -
Financial
Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System
PARSIPPANY, N.J., April 09, 2019 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (“Pacira”) (NASDAQ: PCRX) today announced that it has completed its previously…
Read More »